With hit-and-miss da­ta, Al­lakos goes the pub­lic of­fer­ing route in $150M ask

Cal­i­for­nia-based biotech Al­lakos, which works on al­ler­gies and in­flam­ma­tion-re­lat­ed dis­eases, is mak­ing hay while the sun shines.

Ten days af­ter an­nounc­ing luke­warm re­sults of its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER